Skip to main content

16-10-2018 | Psoriatic arthritis | Review | Article

Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review

Clinical Rheumatology

Authors: Maxime Sondag, Frank Verhoeven, Xavier Guillot, Clément Prati, Daniel Wendling

Publisher: Springer London


Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really codified. We performed a complementary literature review (since a previous one in 2014) of efficacy of new treatments recently used in PsA on this specific clinical manifestation. Eleven publications were retained (4697 patients). In the randomized double-blind placebo-controlled trials analyzed, authors declared ustekinumab, ixekizumab, adalimumab, and apremilast efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective. Calculations of odds ratios for residual dactylitis were significant for clazakizumab 100 mg and secukinumab in anti-TNF-naïve population. Homogenization of dactylitis assessment and use of this criterion as primary outcome are necessary to have better data on treatment efficacy in the future.

Please log in to get access to this content

Related topics